IPO前估值40.38亿元。 本文为IPO早知道原创 作者｜罗宾 微信公众号｜ipozaozhidao 据IPO早知道消息，北京五和博澳药业股份有限公司（下称"五和博澳"）于2月27日向港交所递交招 股说明书，拟主板挂牌上市，华泰国际担任独家保荐人。 五和博澳成立于2010年，为一家立足"天然药物"创新主线，专注于高技术壁垒原创新药研发、产业 化及商业化的生物医药公司，聚焦代谢性疾病、恶性肿瘤等重大疾病治疗领域。此外，五和博澳还开 展了药物递送系统（DDS）的研发，旨在突破体内药物递送的技术瓶颈。 公司核心产品"桑博恩®"（WH001桑枝总生物碱片）为中药1.2类创新药，已于2020年3月获批上 市，据灼炽咨询，中国首个及唯一获批上市用于血糖控制的原创天然药物，也是全球首个植物来源有 效组分降血糖天然药物。"桑博恩"于同年纳入国家医保药品目录。 公司从糖尿病治疗先行，进一步拓展肥胖、MASH、PCOS等代谢紊乱相关疾病治疗的新适应症，为 代谢相关复杂疾病的异病同治提供具有系统治疗能力的天然药物，有望填补国际空白。除商业化产 品，公司拥有8款在研候选药物，包括三款核心在研产品WH007、WH006、WH002。 ...

Core Insights - The 28th Beijing-Taipei Technology Forum focused on "Innovation-Driven Integrated Development: Jointly Building a New Ecosystem for the Biotechnology Industry" and gathered representatives from both regions to discuss trends and collaboration opportunities in the biopharmaceutical sector [1][2] Group 1: Policy and Regulatory Framework - The Deputy Director of Beijing's Drug Administration highlighted the "Measures to Support the High-Quality Development of Innovative Pharmaceuticals in Beijing (2025)", emphasizing policies related to clinical trials, approval processes, production, circulation, clinical application, and investment support [1] - The administration aims to enhance innovation services, expedite review processes, and improve inspection efficiency to promote high-quality development in the pharmaceutical and health industry [1] Group 2: Industry Trends and Innovations - Discussions included topics such as natural drug development, ADC innovation technology, cell and gene therapy, AI-assisted pathology diagnosis, and exosome technology [1] - Companies like Tianjin Biotechnology Group and Yuyuan Pharmaceutical shared insights on their innovative products, including the first approved natural new drug for diabetic foot ulcers and advancements in ADC technology [1][2] - The Chinese innovative pharmaceutical industry is transitioning from a "follower" to a key global innovator, with ongoing improvements needed in original innovation capabilities and global competitiveness [1] Group 3: Industry Growth and Economic Impact - The Beijing Economic and Technological Development Zone hosts over 5,000 companies in the biotechnology and health sector, with projected industrial output value of 81.3 billion yuan in 2024 and a 16.6% year-on-year revenue growth in the technology service sector [2] - The establishment of the International Pharmaceutical Innovation Park (BioPark) has attracted major international companies like AstraZeneca, Eli Lilly, Pfizer, and Bayer, with all six centers of the National Medical Products Administration now located there [2]

Group 1: Company Developments - Iwubio has completed a clinical trial for its "Artemisia pollen allergen sublingual drops," demonstrating long-term efficacy and safety for adult patients with allergic rhinitis, providing evidence for clinical long-term use [1] - The company reported a net profit of 166 million to 181 million yuan for the first half of the year, representing a year-on-year growth of 16.96% to 27.56% [3] - Iwubio's product sales include 455 million yuan for dust mite drops, 21.02 million yuan for Artemisia pollen drops, and 6.32 million yuan for skin prick solution, with respective year-on-year growth rates of 10.51%, 71.37%, and 104.38% [3] Group 2: Market Position and Strategy - Iwubio is a leading player in the domestic desensitization treatment market, focusing on the development of allergen products and expanding into stem cell and natural medicine research [3][4] - The company has established a strong R&D team to enhance its innovation capabilities and maintain its market leadership [4] - Iwubio is the only company in China with two approved sublingual allergen desensitization products, providing a competitive edge in the desensitization treatment field [4] Group 3: Industry Trends - The global allergy treatment market is projected to reach 31.07 billion USD by 2029, with a compound annual growth rate of 8.10% from 2024 to 2029 [2] - The increasing prevalence of allergic diseases poses significant public health challenges, necessitating effective prevention and treatment strategies [2][6] - Iwubio aims to become an international leader in the pharmaceutical industry while ensuring long-term development and returns for shareholders and employees [6]